Fresenius Group Overview

  • H1 & Q2 2018 Results

    Fresenius posts strong second quarter and confirms Group guidance – Continued net income growth – EBIT outlook raised for Fresenius Kabi

New Developments

Financial Highlights

Sales

€ 8382 m

+5%1, 2

Q2/2017: €8,401 m2

EBITDA3

€ 1509 m

+3%1

Q2/2017: €1,538 m

EBIT

€ 1145 m

+2%1

Q2/2017: €1,177 m

Employees

273,632

Dec. 31, 2017: 273,249

Net Income3

€ 472 m

+7%1

Q2/2017: €459 m

Earnings per Share3

€ 0.85

+7%1

Q2/2017: €0.82

1 In constant currency, before special items
2 Adjusted for IFRS 15 adoption
3 Net income attributable to shareholders of Fresenius SE & Co. KGaA

CEO message

“The first half of 2018 was a very good one for Fresenius. After our successful start, we have delivered a strong second quarter with continued healthy growth in sales and earnings. All four business segments contributed to this, and all four business segments display outstanding prospects for the future. For Fresenius Kabi, we are even a bit more optimistic than before. We are therefore fully on track to achieve our ambitious growth targets as we steer toward another excellent year for Fresenius.”


Stephan Sturm, Chairman of the Management Board 

  • Business Segments

    • Q2/2018 reported results significantly positively influenced by divestitures of Care Coordination activities
    • 5% adjusted sales growth in constant currency
    • 6% adjusted net income growth in constant currency
    • 22% net income growth in constant currency on a comparable basis

  • Business Segments

    • 6% organic sales growth and 11% EBIT growth in constant currency (excluding biosimilars business)
    • European Commission confirms marketing authorizations of HES subject to the implementation of risk minimization measures
    • Sales outlook confirmed
    • EBIT outlook raised

  • Business Segments

    • 4% organic sales growth
    • DRG catalogue effects and preparatory structural activities for anticipated regulatory measures weigh on financial performance of Helios Germany
    • Helios Spain with accelerated growth: 8% organic sales growth and 19% EBIT growth
    • 2018 outlook confirmed

  • Business Segments

    • Service business with continued good momentum: 11% sales growth
    • Project business with good order intake of €195 million
    • Transfer of inpatient post-acute care business from Helios Germany to Vamed as of July 1, 2018
    • 2018 outlook confirmed

Fresenius Helios opens new hospital in Cordoba

Quirónsalud, the Spanish hospital group that is part of Fresenius Helios, opened a new hospital in Cordoba on September 17, 2018. The company now has six hospitals in Andalusia, Spain’s most southernly autonomous community. Quirónsalud has invested €50 million in the new hospital.

 

Cross-border knowledge exchange between Helios and Quirónsalud creates basis for further growth.

  • Helios Germany & Helios Spain

    With the acquisition of Quirónsalud, Fresenius Helios has strengthened its position as Europe's largest private hospital operator.

    • Mid-term synergies of approx. €50 m p.a. expected
    • Patients benefit from exchange of knowledge and experience
    • Opportunities for further international growth
  • Exchange of Knowledge and Expertise

    Quality: Helios Spain has already begun to implement the system developed by Helios Germany for measuring and assessing data on medical quality

    Digitalization: Helios Spain’s advanced know-how in patient-oriented uses includes the development of apps, while Helios Germany is particularly strong in IT processes. 

    Different health care systems: Fresenius Helios can now draw on its experience from two different health care systems with respect to inpatient and outpatient care. The two are strictly separated in Germany, but less so in Spain.

  • The German Hospital Market

    German Acute Care Hospital Market:~ €98 bn*

    Growth opportunities for Helios:

    • Aging population
    • Specialized centers
    • Development of new business areas


    * German Federal Statistical Office 2017; total costs, gross of the German hospitals less academic research and teaching

     

  • The Spanish Hospital Market

    Spanish Private Hospital Market: ~ € 14 bn**

    Growth opportunities for Helios:

    •   Aging population
    •   Increasing number of privately insured patients
    •   Greenfield projects
    •   Market consolidation

    * Market definition does neither include Public Private Partnerships (PPP) nor Occupational Risk Prevention centers (ORP)

  • Stephan Sturm

    “Helios Germany and Quirónsalud are bundling their respective strengths across national borders, exchanging experience and knowledge. This benefits our patients, in Spain as well as in Germany. And it is creating, step by step, the economic prerequisites for the further internationalization of our hospital business. The driving force behind our business success is, and will remain, our clear focus on the well-being of patients. So wherever and whenever we can do more for our patients through closer cooperation between our business segments, we will seize that opportunity.”

    Chairman of the Management Board, Fresenius Management SE

  • Dr. Francesco De Meo

    “Helios Germany and Quirónsalud are leaders in their home markets, each of which has different reimbursement and care models and health insurance systems. In response, each company has developed its own strengths, which excellently complement each other and can be used to their mutual advantage. We expect this will contribute to higher medical quality and more efficiency, and bring us closer to patients. Thus, together we are building a common base of knowledge and experience that will help us to enter new markets.”

     

    CEO Helios Health

News

All Financial Reports